Prof. Dr. Yeşim Eralp

Abstract PS4-11-08: Clinical characteristics and prognosis in interval detected breast cancer patients: a single institution cohort analysis

Clinical Cancer Research, 2026

DOI 10.1158/1557-3265.sabcs25-ps4-11-08 Source : OpenAlex

Evolving Concepts and Contemporary Management of Early-Stage Breast Cancer: An Evidence-Based Approach to Grey Zones from a Comprehensive Breast Unit Part 1: Locoregional Therapy, Pathology, Radiology

European Journal of Breast Health, 2026

DOI 10.4274/ejbh.galenos.2026.2025-10-1 PMID 41873792 Texte intégral en libre accèsSource : OpenAlex

Preimplantation genetic testing (PGT-M) awareness in BRCA-positive individuals in Türkiye: a dual physician–patient survey

Scientific Reports, 2026

DOI 10.1038/s41598-026-61177-3 PMID 42414499 Texte intégral en libre accèsSource : OpenAlex

Investigating the feasibility of cascade genetic testing for BRCA1/2 in Türkiye: physicians' practices, barriers, and solutions

European Journal of Cancer Care, 2026

DOI 10.48130/ejcc-0026-0010 Source : OpenAlex

DNA Methylation Signatures Distinguish Breast Cancer Histological Subtypes and Predict Hormone Receptor Status: A TCGA-Based Integrative Analysis

Experimed, 2026

DOI 10.26650/experimed.1930098 Texte intégral en libre accèsSource : ORCID

Evolving Concepts and Contemporary Management of Early-Stage Breast Cancer: An Evidence-Based Approach to Grey Zones from a Comprehensive Breast Unit Part 2: Systemic Treatment

European Journal of Breast Health, 2025

DOI 10.4274/ejbh.galenos.2025.2025-10-2 PMID 41447641 Texte intégral en libre accèsSource : OpenAlex

42P Concordance of CanAssist breast with Oncotype Dx and MammaPrint in patients with early stage hormone receptor positive breast cancer

ESMO Open, 2025

DOI 10.1016/j.esmoop.2025.104596 Texte intégral en libre accèsSource : OpenAlex

Metastatic Mixed-Type Liposarcoma of the Popliteal Fossa: Multimodal Treatment

Springer eBooks, 2025

DOI 10.1007/978-3-031-77061-6_31 Source : ORCID

First-line (1L) ribociclib (RIB) + endocrine therapy (ET) vs combination chemotherapy (combo CT) in clinically aggressive hormone receptor (HR)+/HER2− advanced breast cancer (ABC): A subgroup analysis of patients (pts) with or without liver metastases (mets) from RIGHT Choice.

Journal of Clinical Oncology, 2025

DOI 10.1200/jco.2025.43.16_suppl.1069 1 citation (OpenAlex) Texte intégral en libre accèsSource : OpenAlex

Abstract PS2-06: First-line (1L) ribociclib (RIB) + endocrine therapy (ET) vs combination chemotherapy (combo CT) in clinically aggressive HR+/HER2- advanced breast cancer (ABC): a subgroup analysis of RIGHT Choice by intrinsic subtype & gene & signature expression

Clinical Cancer Research, 2025

DOI 10.1158/1557-3265.sabcs24-ps2-06 1 citation (OpenAlex) Source : OpenAlex

A multicenter, retrospective archive study of radiological and clinical features of ALK-positive non-small cell lung cancer patients and crizotinib efficacy

Medicine, 2024

DOI 10.1097/md.0000000000037972 PMID 38787994 2 citations (Europe PMC) Texte intégral en libre accèsSource : OpenAlex

Final Results of RIGHT Choice: Ribociclib Plus Endocrine Therapy Versus Combination Chemotherapy in Premenopausal Women With Clinically Aggressive Hormone Receptor–Positive/Human Epidermal Growth Factor Receptor 2–Negative Advanced Breast Cancer

Journal of Clinical Oncology, 2024

DOI 10.1200/jco.24.00144 PMID 38771995 88 citations (Europe PMC) Texte intégral en libre accèsSource : ORCID

Artificial intelligence algorithms for recurrence risk score prediction in early-stage breast cancer: A multicenter study of 437 cases.

Journal of Clinical Oncology, 2024

DOI 10.1200/jco.2024.42.16_suppl.545 1 citation (OpenAlex) Texte intégral en libre accèsSource : OpenAlex

Demographic and Clinical Features of Patients with Metastatic Breast Cancer: A Retrospective Multicenter Registry Study of the Turkish Oncology Group

Cancers, 2023

DOI 10.3390/cancers15061667 PMID 36980554 4 citations (Europe PMC) Texte intégral en libre accèsSource : OpenAlex

Is there any prognostic significance in pleural involvement and/or effusion in patients with ALK-positive NSCLC?

Journal of Cancer Research and Clinical Oncology, 2023

DOI 10.1007/s00432-023-05190-3 PMID 37480524 2 citations (Europe PMC) Texte intégral en libre accèsSource : OpenAlex

Abstract P3-02-06: Demographic and clinical features of patients with metastatic HER2 positive breast cancer: a retrospective multicenter registry study of the Turkish Oncology Group

Cancer Research, 2023

DOI 10.1158/1538-7445.sabcs22-p3-02-06 Source : OpenAlex

402P First-line ribociclib (RIB) + endocrine therapy (ET) vs combination chemotherapy (combo CT) in aggressive HR+/HER2− advanced breast cancer (ABC): A subgroup analysis of patients (pts) with or without visceral crisis from the phase II RIGHT choice study

Annals of Oncology, 2023

DOI 10.1016/j.annonc.2023.09.579 7 citations (OpenAlex) Texte intégral en libre accèsSource : OpenAlex

Clinical Applications of Combined Immunotherapy Approaches in Gastrointestinal Cancer: A Case-Based Review

Vaccines, 2023

DOI 10.3390/vaccines11101545 PMID 37896948 4 citations (OpenAlex) Texte intégral en libre accèsSource : OpenAlex

456P Quality of life (QOL) analysis from the phase II RIGHT choice study of first-line ribociclib (RIB) + endocrine therapy (ET) vs combination chemotherapy (combo CT) in aggressive HR+/HER2− advanced breast cancer (ABC)

Annals of Oncology, 2023

DOI 10.1016/j.annonc.2023.09.632 1 citation (OpenAlex) Texte intégral en libre accèsSource : OpenAlex

57MO First-line (1L) ribociclib (RIB) + endocrine therapy (ET) vs combination chemotherapy (combo CT) in HR+/HER2− advanced breast cancer (ABC): A post hoc analysis of Asian and non-Asian patients (pts) from the phase II RIGHT choice trial

Annals of Oncology, 2023

DOI 10.1016/j.annonc.2023.10.192 1 citation (OpenAlex) Texte intégral en libre accèsSource : OpenAlex

Abstract GS1-10: Primary results from the randomized Phase II RIGHT Choice trial of premenopausal patients with aggressive HR+/HER2− advanced breast cancer treated with ribociclib + endocrine therapy vs physician’s choice combination chemotherapy

Cancer Research, 2023

DOI 10.1158/1538-7445.sabcs22-gs1-10 42 citations (OpenAlex) Source : OpenAlex

Outcomes with first-line (1L) ribociclib (RIB) + endocrine therapy (ET) vs physician’s choice combination chemotherapy (combo CT) by age in pre/perimenopausal patients (pts) with aggressive HR+/HER2− advanced breast cancer (ABC): A subgroup analysis of the RIGHT Choice trial.

Journal of Clinical Oncology, 2023

DOI 10.1200/jco.2023.41.16_suppl.1063 11 citations (OpenAlex) Source : OpenAlex

The Impact of Hybrid Capture-Based Comprehensive Genomic Profiling on Treatment Strategies in Patients with Solid Tumors

Journal of Oncological Sciences, 2022

DOI 10.37047/jos.2022-89310 Texte intégral en libre accèsSource : OpenAlex

Demographic and clinical features of patients with metastatic HER2 positive breast cancer: a retrospective multicenter registry study of the Turkish Oncology Group

San Antonio Breast Cancer Conference, 2022

Source : ORCID

Laterality and survival in mesothelioma: A SEER database analysis.

Journal of Clinical Oncology, 2022

DOI 10.1200/jco.2022.40.16_suppl.e20594 Source : ORCID

International Association for the Study of Lung Cancer Study of the Impact of Coronavirus Disease 2019 on International Lung Cancer Clinical Trials

Journal of Thoracic Oncology, 2022

DOI 10.1016/j.jtho.2022.01.017 PMID 35183774 6 citations (Europe PMC) Texte intégral en libre accèsSource : ORCID

Abstract P1-01-07: Factors predicting a lower likelihood of residual nodal disease in clinically-node positive patients undergoing sentinel node surgery after neoadjuvant chemotherapy for breast cancer

Cancer Research, 2022

DOI 10.1158/1538-7445.sabcs21-p1-01-07 Source : ORCID

Application of mRNA Technology in Cancer Therapeutics

Vaccines, 2022

DOI 10.3390/vaccines10081262 PMID 36016150 13 citations (Europe PMC) Texte intégral en libre accèsSource : ORCID

Lung Cancer in Turkey

Journal of Thoracic Oncology, 2022

DOI 10.1016/j.jtho.2022.06.001 PMID 36192076 12 citations (Europe PMC) Texte intégral en libre accèsSource : ORCID

1200TiP Phase Ia/Ib study of RS-0139, a novel tumor-targeted delivery of docetaxel, in patients with recurrent, locally advanced, or metastatic non-small cell lung cancer (NSCLC)

Annals of Oncology, 2022

DOI 10.1016/j.annonc.2022.07.1876 1 citation (OpenAlex) Texte intégral en libre accèsSource : OpenAlex

The role of adjuvant chemotherapy in resected stage I non - small cell lung cancer: A Turkish Oncology Group Study.

PubMed, 2021

PMID 34268941 4 citations (Europe PMC) Source : OpenAlex

P84.03 GLASS: Global Lorlatinib for ALK(+) and ROS1(+) Retrospective Study: Real World Data of 123 NSCLC Patients

Journal of Thoracic Oncology, 2021

DOI 10.1016/j.jtho.2021.01.1202 Texte intégral en libre accèsSource : OpenAlex

Outcomes of thymoma after multimodal therapy and determinants of survival: A 16-year experience of a tertiary cancer center

Turkish Journal of Thoracic and Cardiovascular Surgery, 2021

DOI 10.5606/tgkdc.dergisi.2021.20529 PMID 35096446 1 citation (Europe PMC) Texte intégral en libre accèsSource : OpenAlex

TIM3 expression on TILs is associated with poor response to neoadjuvant chemotherapy in patients with locally advanced triple-negative breast cancer

BMC Cancer, 2021

DOI 10.1186/s12885-021-08054-6 PMID 33823818 26 citations (Europe PMC) Texte intégral en libre accèsSource : ORCID

Abstract PS4-32: Tim3 expression on tumor infiltrating lymphocytes is associated with poor response to neoadjuvan chemotherapy in patients with locally advanced triple negative breast cancer

Cancer Research, 2021

DOI 10.1158/1538-7445.sabcs20-ps4-32 Source : ORCID

Correlation between clinicopathologic factors and recurrence score according to TAILOR x risk category in patients with hormone receptor positive early-stage breast cancer

Journal of B.U.ON., 2021

Source : ORCID

The role of adjuvant chemotherapy in resected stage I non - small cell lung cancer: A Turkish Oncology Group Study

Journal of B.U.ON., 2021

Source : ORCID

Tim3 expression on tumor infiltrating lymphocytes is associated with poor response to neoadjuvan chemotherapy in patients with locally advanced triple negative breast cancer

Cancer Research, 2021

Source : ORCID

Determine the impact of hybrid capture-based comprehensive genomic profiling (CGP) on the treatment strategies in patients with solid tumors: A national, multicenter, retrospective study.

Journal of Clinical Oncology, 2020

DOI 10.1200/jco.2020.38.15_suppl.e13646 1 citation (OpenAlex) Source : OpenAlex

Efficacy of Palbociclib and Endocrine Treatment in Heavily Pretreated Hormone Receptor-positive Her2-negative Advanced Breast Cancer: Retrospective Multicenter Trial

Balkan Medical Journal, 2020

DOI 10.4274/balkanmedj.galenos.2019.11.143 PMID 31970972 3 citations (Europe PMC) Texte intégral en libre accèsSource : OpenAlex

GLASS: Global Lorlatinib for ALK(+) and ROS1(+) retrospective Study: real world data of 123 NSCLC patients

Lung Cancer, 2020

DOI 10.1016/j.lungcan.2020.07.022 PMID 32799090 30 citations (Europe PMC) Source : OpenAlex

Abstract P5-11-19: Ribociclib for the treatment of hormone receptor-positive refractory advanced breast cancer: Managed access programme in Turkey

Cancer Research, 2020

DOI 10.1158/1538-7445.sabcs19-p5-11-19 Source : OpenAlex

Retrospective analysis of ribociclib and letrozole as first-line therapy in patients with hormone receptor (HR) positive metastatic breast cancer (MBC) within a managed access program (MAP) in Turkey.

Journal of Clinical Oncology, 2020

DOI 10.1200/jco.2020.38.15_suppl.e13055 Source : OpenAlex

Turkish national consensus on breast cancer management during temporary state of emergency due to COVID-19 outbreak

Turkish Journal of Surgery, 2020

DOI 10.5578/turkjsurg.4815 PMID 33015560 7 citations (Europe PMC) Texte intégral en libre accèsSource : OpenAlex

P2.17-23 The Role Adjuvant Chemotherapy in Resected Stage 1 NSCLC with High Risk Factors: A Turkish Oncology Group Study

Journal of Thoracic Oncology, 2019

DOI 10.1016/j.jtho.2019.08.1934 Texte intégral en libre accèsSource : OpenAlex

P1.14-15 Lorlatinib in ALK- or ROS1-Positive Non-Small Cell Lung Cancer Patients: Experience from an Early Access Program in Turkey

Journal of Thoracic Oncology, 2019

DOI 10.1016/j.jtho.2019.08.1166 3 citations (OpenAlex) Texte intégral en libre accèsSource : OpenAlex

Is there any prognostic significance in pleural involvement and/or effusion (Ple-I/E) in patients with ALK-positive NSCLC?

Annals of Oncology, 2019

DOI 10.1093/annonc/mdz260.069 Texte intégral en libre accèsSource : OpenAlex

EP1.15-11 Outcomes of Thymoma and Determinants of Survival: 16 Years Experience of a Tertiary Cancer Center

Journal of Thoracic Oncology, 2019

DOI 10.1016/j.jtho.2019.08.2346 1 citation (OpenAlex) Texte intégral en libre accèsSource : OpenAlex

Ribociclib plus goserelin with hormonal therapy versus physician choice chemotherapy in pre-/perimenopausal patients with HR+, HER2– inoperable locally advanced breast cancer (ABC): RIGHT choice study

Annals of Oncology, 2019

DOI 10.1093/annonc/mdz417.010 Texte intégral en libre accèsSource : ORCID

RIbociclib plus goserelin with hormonal therapy versus physician choice chemotherapy in premenopausal or perimenopausal patients with HR+, HER2– inoperable locally advanced or metastatic breast cancer: RIGHT choice study

Annals of Oncology, 2019

DOI 10.1093/annonc/mdz242.081 1 citation (OpenAlex) Texte intégral en libre accèsSource : ORCID